Company / EPS (Diluted)
Gain Therapeutics, Inc. EPS (Diluted) History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.71
FY2024
5-year range
-$1.71 / -$1.33
FY2021-FY2024
Trend
-15.5%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Diluted) has declined for 3 consecutive years, from $-1.33 in FY2021 to $-1.71 in FY2024.
Based on SEC 10-K filings.
-1.71 in FY2024.
Declined from $-1.37 to $-1.71 over the past 2 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Gain Therapeutics, Inc.'s eps (diluted) has declined for 3 consecutive years.
- In FY2024, eps (diluted) decreased 15.5% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$1.71 | -15.5% |
| FY2023 | -$1.48 | -8.0% |
| FY2022 | -$1.37 | -3.0% |
| FY2021 | -$1.33 | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026